ATAI Life Sciences Prices Offering, Shares Surge 17.7%

By Tamara Parker • Monday, October 20 15:38 • Permanent Link

Atai Life Sciences, a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, recently announced the pricing of a registered underwritten offering of 23,725,000 common shares at a price of $5.48 per share. This offering is expected to generate gross proceeds of approximately $130 million. The company intends to use the net proceeds, along with existing cash, cash equivalents, and short-term investments, to advance the clinical development of its product candidates and programs, as well as for working capital and general corporate purposes.

The underwriters have been granted a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. The offering is expected to close on October 20, 2025, subject to customary closing conditions.

Jefferies LLC is serving as the lead bookrunner for the offering, with Berenberg Capital Markets LLC acting as a passive bookrunner, and Oppenheimer & Co. Inc. and Canaccord Genuity LLC serving as co-managers for the offering.

The company's pipeline of psychedelic-based therapies includes BPL-003 (intranasal mebufotenin benzoate) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) also for TRD, and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in phase 2 clinical development. Additionally, Atai is advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD and opioid use disorder.

The offering is being made pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission on September 29, 2025. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Today the company's shares have moved 17.7% to a price of $6.45. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.